Combining molecular markers with the TNM staging system to improve prognostication in stage II and III colon cancer: are we ready yet?
Combining molecular markers with the TNM staging system to improve prognostication in stage II and III colon cancer: are we ready yet?
复制标题
将分子标志物与 TNM 分期系统相结合，改善 II 期和 III 期结肠癌的预后：我们准备好了吗？
DOI：
10.1093/jnci/djs441
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Shi,Qian
中科院分区：
文献类型：
--
作者：
Sinicrope,FrankA;Shi,Qian
5. Kellert IM, Botterweck AA, Huveneers JA, et al. Trends in incidence of and mortality from uterine and ovarian cancer in Mid and South Limburg, The Netherlands, 1986–2003. Eur J Cancer Prev. 2009; 18 (1): 85–89. 6. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA. 2007; 298 (10): 1209–1212.7. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004; 92 (3): 744–751. 8. Lindemann K, Onsrud M, Kristensen G, et al. Survival after radiation therapy for early-stage endometrial carcinoma: the Oslo study revisited after up to 43 years of follow-up. J Clin Oncol. 2012; 30 (suppl): abstr 5008. 9. Creutzberg CL, van Putten WL, Koper PC, et al.; PORTEC Study Group. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000; 355 (9213): 1404–1411.
